Table 3.
Characteristics of the included studies
| Author (Year) | Origin country | Study type | Total patients# |
Age (in years) Mean±SD (range) | Modalities used | Research object | Tumor staging | MRI machine | MRI sequence | Time between MRI recording and tumor resection | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | ||||||||||
| Alsaffar et al. (2016)[99] | Canada | Prospective | 53 | 64 | Clinical, MRI, histopathological | DOI | T1–T4 | NP | NP | NP | |
| 34 | 19 | ||||||||||
| Jayasankaran et al. (2017)[96] | India | Prospective | 59 | 51.81 (18–74) | Clinical, MRI, histopathological | DOI Infiltration of sublingual space Infiltration of extrinsic muscles Involvement of mylohyoid muscle | T1–T4 | 3.0 Tesla | T1WI spin echo T2WI T2WI with FS T1WI with FS | Less than 1 week | |
| 42 | 17 | ||||||||||
| Moreno et al.* (2017)[98] | USA | Prospective | 20 | 58 (29–80) | Clinical, MRI, histopathology | DOI Cervical LN metastasis | T1–T4 | 3.0 Tesla | T1WI T2WI | 1–40 days | |
| 14 | 6 | ||||||||||
| Baba et al. (2019)[91] | Japan | Retrospective | 28 | 66.2±15.2 (31–86) | Clinical, MRI, histopathological | DOI Locoregional control rate Disease-free SR Overall SR | T1–T2 | 1.5 Tesla | T1WI T2WI T1WI with FS | NP | |
| 18 | 10 | ||||||||||
| Mao et al. (2019)[93] | China | Prospective | 150 | 58.01±12.10 | Clinical, MRI, histopathological | DOI Disease-specific SR Overall SR | T1–T3 | 1.5 Tesla | T1WI T2WI T2WI with FS | 1 week | |
| 80 | 70 | ||||||||||
| Murakami et al. (2019)[90] | Japan | Retrospective | 29 | (46–87) | Clinical, MRI, histopathological | DOI Recurrence pattern | T2 | 3.0 Tesla | T1WI T2WI CE T1WI STIR | 1 month | |
| 15 | 14 | ||||||||||
| Baba et al. (2019)[92] | Japan | Retrospective | 45 | 63.4±16.1 (31–86) | Clinical, MRI, histopathological | DOI Cervical LN metastasis Locoregional control rate Disease-free SR Overall SR | T1–T2 | 1.5 Tesla | T1WI T2WI T1WI with FS | NP | |
| 31 | 14 | ||||||||||
| Vidiri et al.≤ (2020)[6] | Italy | Retrospective | 43 | (31–82) | Clinical, MRI, histopathological | DOI | T1–T3 | 1.5 Tesla | T1WI T2WI | 3–4 weeks | |
| 18 | 25 | ||||||||||
| Ravikanth (2020)[97] | India | Prospective | 30 | (41–70) | Clinical, MRI, Histopathological | DOI Cervical LN metastasis | T1–T4 | 1.5 Tesla | T1WI T2WI | NP | |
| 27 | 3 | ||||||||||
| Xu et al. (2020)[87] | China | Retrospective | 151 | 57.1 (30–78) | Clinical, MRI, histopathological | DOI Cervical LN metastasis Disease-specific SR | T1 | 3.0 Tesla | T1WI T2WI T2WI with FS | 1 week | |
| 111 | 40 | ||||||||||
| Fu et al. (2020)[95] | China | Retrospective | 156 | 58.7±9.2 (27–92) | Clinical, MRI, histopathological | DOI | T1–T3 | 3.0 Tesla | T1WI spin echo T2WI turbo spin echo T1WI with FS | NP | |
| 95 | 61 | ||||||||||
| Haraguchi et al. (2021)[88] | Japan | Retrospective | 101 | 63.9 (22–88) | Clinical, MRI, histopathological | DOI Cervical LN metastasis | T1–T4 | NP | T1WI T2WI | NP | |
| 57 | 44 | ||||||||||
| Baba et al. (2021)[1] | Japan | Retrospective | 21 | NP | Clinical, MRI, CT, histopathological | DOI | T1–T3 | 1.5 Tesla | T2WI T1WI with FS | NP | |
| 16 | 5 | ||||||||||
| Huopainen et al. (2021)[89] | Finland | Retrospective | 45 | NP | Clinical, MRI, histopathological | DOI | T1–T3 | 1.5 Tesla or 3.0 Tesla | T1WI with FS | NP | |
| NP | |||||||||||
| Mair et al. (2021)[100] | UK | Retrospective | 60 | 56.7 | Clinical, MRI, histopathological | DOI | T1–T4 | 1.5 Tesla | Post-contrast, FS T1WI | 2 weeks | |
| 40 | 20 | ||||||||||
| Takamura et al. (2022)[8] | Japan | Retrospective | 48 | 65.7 (23–90) | Clinical, MRI, US, histopathological | DOI | T1–T2 | 1.5 Tesla | T1WI with FS T2WI with FS | 8–34 days | |
| 28 | 20 | ||||||||||
| Tang et al. (2022)[94] | China | Retrospective | 122 | (28–76) | Clinical, MRI, histopathological | DOI | T1–T3 | 3.0 Tesla | T1WI T2WI with FS DWI e-THRIVE | 2 weeks | |
| 78 | 44 | ||||||||||
#Patients with tongue carcinoma included in the analysis; *: the author used the term tumor thickness, which was confirmed to be DOI measurement after reading the full text
M: male; F: female; SD: standard deviation; MRI: magnetic resonance imaging; DOI: depth of invasion; NP: not provided; T1WI: T1-weighted image; T2WI: T2-weighted image; T: tumor; FS: fat suppression; CE: contrast-enhanced; STIR: short tau inversion recovery; SR: survival rate; CT: computed tomography; ≤: only mean difference was provided; LN: lymph node; US: ultrasound; DWI: diffusion-weighted image; e-THRIVE: dynamic enhanced T1 high-resolution isotropic volume examination